sumatriptan has been researched along with Mental Disorders in 6 studies
Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.
sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.
Mental Disorders: Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sumatriptan was the first medication of this group." | 1.40 | Sumatriptan in clinical practice: effectiveness in migraine and the problem of psychiatric comorbidity. ( Lionetto, L; Martelletti, P; Napoletano, F, 2014) |
| "The lifetime prevalence of several psychiatric disorders was determined by the National Institute of Mental Health diagnostic interview schedule and personality factors were measured by the 16 Personality Factors (16PF) Questionnaire." | 1.31 | Sumatriptan responsiveness and clinical, psychiatric and psychologic features in migraine patients. ( Becker, WJ; Dalby, JT; Meckling, SK; Rose, MS, 2001) |
| "Serotonin syndrome has been reported exclusively in patients on medications for psychiatric illness and Parkinsonism, despite the fact that the putative action of many antimigraine agents also involves the serotonin system." | 1.29 | Serotonin syndrome complicating migraine pharmacotherapy. ( Lucker, C; Mathew, NT; Tietjen, GE, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishii, M | 1 |
| Katoh, H | 1 |
| Imawaka, M | 1 |
| Kasai, H | 1 |
| Ishibashi, M | 1 |
| Napoletano, F | 1 |
| Lionetto, L | 1 |
| Martelletti, P | 1 |
| Fuller, RW | 1 |
| Bakshi, R | 1 |
| Yan-Go, FL | 1 |
| Mathew, NT | 1 |
| Tietjen, GE | 1 |
| Lucker, C | 1 |
| Meckling, SK | 1 |
| Becker, WJ | 1 |
| Rose, MS | 1 |
| Dalby, JT | 1 |
1 review available for sumatriptan and Mental Disorders
| Article | Year |
|---|---|
Mechanisms and functions of serotonin neuronal systems: opportunities for neuropeptide interactions.
Topics: Animals; Central Nervous System; Corticotropin-Releasing Hormone; Female; Mental Disorders; Migraine | 1996 |
5 other studies available for sumatriptan and Mental Disorders
| Article | Year |
|---|---|
[Therapeutic Effects of Intranasal Sumatriptan for Cluster Headache].
Topics: Administration, Intranasal; Adolescent; Adult; Age Factors; Age of Onset; Child; Cluster Headache; F | 2019 |
Sumatriptan in clinical practice: effectiveness in migraine and the problem of psychiatric comorbidity.
Topics: Antidepressive Agents; Drug Interactions; Humans; Mental Disorders; Migraine Disorders; Monoamine Ox | 2014 |
Prolonged marijuana-like dysphoria after subcutaneous sumatriptan.
Topics: Adult; Cannabis; Female; Humans; Injections, Subcutaneous; Mental Disorders; Serotonin Receptor Agon | 1996 |
Serotonin syndrome complicating migraine pharmacotherapy.
Topics: Adult; Autonomic Nervous System Diseases; Dihydroergotamine; Drug Synergism; Female; Gastrointestina | 1996 |
Sumatriptan responsiveness and clinical, psychiatric and psychologic features in migraine patients.
Topics: Adult; Female; Humans; Male; Menstrual Cycle; Mental Disorders; Middle Aged; Migraine Disorders; Neu | 2001 |